Novartis To Consider “Off Shoring” Some Corporate Functions To India
Executive Summary
Novartis will consider "off shoring" certain corporate functions to India
You may also be interested in...
Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say
The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles
Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say
The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles
Clinical Trials Computerized Systems Guidance Issued; GSK Sees Savings
GlaxoSmithKline expects significant savings through the elimination of data managers as the company moves to computerize its clinical trial data, the company said